Marvell Technology Group
plummeted following the close Monday after the Santa Clara, Calif., chipmaker said third-quarter revenue will be lower than expected.
The company also told investors it will restate past financial results due to discrepancies in its past stock-option grants. The company said revenue in its fiscal third quarter will be down about 10% from the $574 million in second-quarter sales.
Analysts polled by Thomson Financial were looking for revenue to rise about 1.4% sequentially, to $582.3 million. EPS is projected to be 21 cents. Separately, Marvell said that a special committee of its board of directors looking into past stock-option practices has reached a preliminary conclusion that the actual measurement dates of certain past stock-option grants likely differ from the recorded grant dates for such awards.
As a result, Marvell's board has concluded that the company will need to restate previous financial statements to record additional noncash charges for stock-based compensation expenses. Shares were tumbling $2.94, or 15.40%, to $16.15.
shares advanced after the New Hope, Minn.-based video-game publisher said its Navarre Distribution Services division signed a distribution supply agreement in which it will supply
with third-party software titles for its U.S. retail locations. Navarre shares were gaining 11 cents, or 2.72%, to $4.15.
lost ground after the Mountain View, Calif.-based chipmaker said it was reviewing its past stock-option-granting practices. The company said a special committee of Actel's board is leading the effort and has retained independent legal counsel to assist. Actel said it informed the
Securities and Exchange Commission
about the internal review.
Also, the company said that a complaint was filed on Aug. 30, in the U.S. District Court for the Northern District of California, by Frank Brozovich, on behalf of Actel, against certain officers and directors. The derivative legal action relates to certain options grants that were allegedly backdated, the company said. Shares were trading down 21 cents, or 1.4%, to $15.
retreated after the South San Francisco, Calif.-based biopharmaceutical company said an interim analysis following the first stage of a two-stage phase II clinical trial for Ispinesib, its treatment for recurrent and metastatic head-and-neck squamous-cell carcinoma, determined that the drug did not satisfy the criteria for advancement to Stage 2.
The best overall response to date in the clinical trial was disease stabilization, the company said, which was observed in five of 19 patients. Ispinesib is being developed in collaboration with
. Shares of Cytokinetics were trading down 52 cents, or 8.19%, to $5.83.
( CKR) gained after Standard & Poor's said the Carpinteria, Calif.-based restaurant chain will replace
Ryan's Restaurant Group
( RYAN) on the S&P Small-Cap 600 after the close of trading on Thursday. Ryan's is being acquired by
in a deal expected to close on or about that day, Standard & Poor's said. Shares were climbing 43 cents, or 2.57%, to $17.15.
Bright Horizons Family Solutions
rose after Standard & Poor's said the Watertown, Mass.-based company will replace
( FILE) on the S&P Small-Cap 600 after the close of trading on a date to be announced. FileNet is being acquired by
in a deal awaiting final approval. Shares were climbing 77 cents, or 1.91%, to $41.06.